XOMA ROYALTY CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.92 USD | -0.91% |
|
-0.48% | -0.80% |
| Jul. 10 | XOMA Corporation will Change its Name to XOMA Royalty Corporation | CI |
| Jul. 09 | Xoma Changes Name to Xoma Royalty | MT |
Financials (USD)
| Sales 2024 * | 21M | Sales 2025 * | 26.93M | Capitalization | 314M |
|---|---|---|---|---|---|
| Net income 2024 * | -22M | Net income 2025 * | -15M | EV / Sales 2024 * | 14.9 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.7 x |
| P/E ratio 2024 * |
-14.2
x | P/E ratio 2025 * |
-20.5
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.47% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.91% | ||
| 1 week | -0.48% | ||
| Current month | -1.74% | ||
| 1 month | -0.97% | ||
| 3 months | -0.32% | ||
| 6 months | +3.83% | ||
| Current year | -0.80% |
1 week
24.86
25.28
1 month
24.8025.40
Current year
23.5025.85
1 year
20.4325.85
3 years
20.4327.95
5 years
20.4327.95
10 years
20.4327.95
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 22-12-31 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 06-08-13 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 21-08-05 |
| Chairman | 68 | 10-08-25 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12-12-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 24.92 | -0.91% | 5,399 |
| 24-07-15 | 25.15 | -0.51% | 1,750 |
| 24-07-12 | 25.28 | +0.72% | 672 |
| 24-07-11 | 25.1 | -0.63% | 1,848 |
| 24-07-10 | 25.26 | +0.87% | 2,244 |
Delayed Quote Nasdaq, July 16, 2024 at 04:30 pm EDT
More quotes
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
27
USD
Average target price
58
USD
Spread / Average Target
+114.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.17% | 127B | |
| +24.67% | 117B | |
| +25.44% | 27.67B | |
| -17.74% | 20.33B | |
| -15.17% | 16.79B | |
| -15.21% | 15.63B | |
| +11.91% | 14.84B | |
| -47.10% | 14.65B | |
| +54.50% | 14.43B |
- Stock Market
- Equities
- XOMA Stock
- XOMAO Stock
